Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.

A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.

Lo SS, Khorana AA, Javle M, Simon S, Kiefer G, Rajasenan K, Wang H, Hantel A, Shayne M, Hwang J, Schmotzer A, Ramanathan RK.

Oncology. 2010;78(2):125-9. doi: 10.1159/000312654. Epub 2010 Apr 13.

PMID:
20389134
2.
3.

Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.

Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA 3rd, Hainsworth JD.

J Clin Oncol. 2010 May 1;28(13):2213-9. doi: 10.1200/JCO.2009.24.8773. Epub 2010 Mar 29.

PMID:
20351330
4.

Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.

Evans D, Miner T, Iannitti D, Akerman P, Cruff D, Maia-Acuna C, Harrington D, Habr F, Chauhan B, Berkenblit A, Stuart K, Sears D, Kennedy T, Safran H.

Cancer Invest. 2007 Sep;25(6):445-8.

PMID:
17882656
5.

Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.

Sym SJ, Ryu MH, Kang HJ, Lee SS, Chang HM, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK.

Cancer Chemother Pharmacol. 2010 Jul;66(2):373-80. doi: 10.1007/s00280-009-1171-x. Epub 2009 Nov 21.

PMID:
19936751
6.

A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.

Evans D, Miner T, Akerman P, Millis R, Jean M, Kennedy T, Safran H.

Am J Clin Oncol. 2007 Aug;30(4):346-9.

PMID:
17762433
7.

Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.

Kim JG, Sohn SK, Kim DH, Baek JH, Sung WJ, Park JY, Kim TB, Jung HY, Yu W, Lee KB.

Oncology. 2005;68(2-3):190-5. Epub 2005 Jul 4.

PMID:
16006756
8.

Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.

Polyzos A, Felekouras E, Karatzas T, Griniatsos J, Dimitroulis D, Polyzos K, Kontzoglou K, Mantas D, Karavokyros J, Nikiteas N, Tsavaris N, Syrigos K, Vafiadis I.

Anticancer Res. 2012 Sep;32(9):4151-6.

PMID:
22993377
9.

Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.

Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F.

Br J Cancer. 2005 Jun 20;92(12):2129-33.

10.
11.

A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.

Evans TR, Pentheroudakis G, Paul J, McInnes A, Blackie R, Raby N, Morrison R, Fullarton GM, Soukop M, McDonald AC.

Ann Oncol. 2002 Sep;13(9):1469-78.

PMID:
12196374
12.

Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.

Giordano KF, Jatoi A, Stella PJ, Foster N, Tschetter LK, Alberts SR, Dakhil SR, Mailliard JA, Flynn PJ, Nikcevich DA; North Central Cancer Treatment Group.

Ann Oncol. 2006 Apr;17(4):652-6. Epub 2006 Feb 23.

PMID:
16497828
13.

[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].

Zhang J, Xiao Y, Lu M, Li J, Zhang XD, Li Y, Shen L.

Zhonghua Zhong Liu Za Zhi. 2009 Apr;31(4):312-5. Chinese.

PMID:
19615292
14.

Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.

Tsai JY, Iannitti D, Berkenblit A, Akerman P, Nadeem A, Rathore R, Harrington D, Roye D, Miner T, Barnett JM, Maia C, Stuart K, Safran H.

Am J Clin Oncol. 2005 Aug;28(4):329-33.

PMID:
16062072
15.

Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.

Di Lauro L, Vici P, Belli F, Tomao S, Fattoruso SI, Arena MG, Pizzuti L, Giannarelli D, Paoletti G, Barba M, Sergi D, Maugeri-Saccà M.

Gastric Cancer. 2014 Oct;17(4):718-24. doi: 10.1007/s10120-013-0321-3. Epub 2013 Dec 8.

PMID:
24318671
16.

Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.

Amarantidis K, Xenidis N, Chelis L, Chamalidou E, Dimopoulos P, Michailidis P, Tentes A, Deftereos S, Karanikas M, Karayiannakis A, Kakolyris S.

Oncology. 2011;80(5-6):359-65. doi: 10.1159/000330199. Epub 2011 Jul 29.

PMID:
21811088
17.

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.

Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J; Australasian Gastro-Intestinal Trials Group.

Br J Cancer. 2010 Feb 2;102(3):475-81. doi: 10.1038/sj.bjc.6605522. Epub 2010 Jan 12.

18.

Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.

Rivera F, Massutí B, Salcedo M, Sastre J, Martínez Galán J, Valladares-Ayerbes M, Serrano R, García de Paredes ML, Manzano JL, Galán M, Alsina M, Yuste Izquierdo AL, López C, Díaz-Rubio E, Conde V, Reboredo M, Cano MT, Pachón V, Aranda E.

Cancer Chemother Pharmacol. 2015 Feb;75(2):319-24. doi: 10.1007/s00280-014-2641-3. Epub 2014 Dec 10.

PMID:
25491381
19.

Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.

Liu C, Sun Q, Hang X, Zhong B, Wang D.

Anticancer Drugs. 2008 Sep;19(8):825-31. doi: 10.1097/CAD.0b013e32830c457e.

PMID:
18690095
20.

Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.

Bilici A, Selcukbiricik F, Demir N, Oven Ustaalioglu BB, Dikilitas M, Yildiz O.

Asian Pac J Cancer Prev. 2014;15(20):8661-6.

Supplemental Content

Support Center